King Faisal Specialist Hospital & Research Centre in Riyadh (KFSH&RC-R), is recognized internationally for its world-class facility, latest medical technology and equipment, experienced and professional doctors and health care providers, and excellent medical care. KFSH&RC-R opened in 1975 and is located close to Riyadh’s city center. The hospital has reached an international standard of excellence equivalent to that of leading global academic medical centers. KFSH&RC-R focuses primarily on research in the field of cancer, cardiovascular diseases, transplant immunology, genetics, molecular diagnostics, and proteomics. The facility has maintained the highest standards in specialized medical care in an integrated educational and research environment.
Department of Adult Critical Care Medicine
Heart Center of Excellence Department
Department of Kidney and Pancreas Health Center
Department of Liver & Small Bowel Health Center
Department of Lung Transplant Health Care Centre
|
Welcome to the Medicine Department
The Medicine department is one of the largest departments at KFSH&RC. It encompasses various specialties including Internal medicine, Nephrology, Gastroenterology, Pulmonology, Endocrinology, Infectious diseases, Rheumatology and Allergy & Immunology with over 129 working physicians and 97 residents.
In alignment with KFSH&RC's Vision 2022, the digital library pertaining to Medicine will aim to educate future healthcare leaders and utilize innovative methods and technologies to deliver high quality healthcare services. Therefore, it will act as a knowledge hub with ample resources ranging from books and medical journals to interactive videos and web resources. If you would like additional help with your Medicine Department research projects, or on learning how to use Library resources, don't hesitate to contact Library through email ILL@kfshrc.edu.sa.
Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03672-0
A human cellular and molecular atlas of the proliferative endometrium in polycystic ovary syndrome (PCOS) was generated via single-nucleus RNA sequencing and spatial transcriptomics. This study reveals PCOS-specific alterations in cellular composition and gene expression, and identifies potential therapeutic targets. These findings could advance treatments for PCOS-related endometrial dysfunction and associated health challenges.Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03689-5
Author Correction: Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adultsNature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03649-z
The World Health Organization’s inaugural Investment Round aims to instill stability in the face of global health headwinds and a US exit.Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03608-8
The ONCOBIOME network has generated new tools to measure dysbiosis and completed numerous trials aimed at modifying the microbiota to enhance cancer treatment; this Review summarizes the key advances and the progress toward translating them into clinical practice.Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03615-9
This Review summarizes recent and compelling examples of microbiome-based interventions that are ripe for clinical adoption while also discussing the challenges and opportunities facing the field.Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03630-w
In the OptiTROP-Breast01 phase 3 trial, patients with metastatic triple-negative breast cancer who received the TROP2-targeted antibody–drug conjugate sacituzumab tirumotecan experienced longer progression-free survival than patients treated with chemotherapy.Nature Medicine, Published online: 11 April 2025; doi:10.1038/s41591-025-03621-x
Intracytoplasmic sperm injection, usually reserved for cases of male infertility, was found to be nonsuperior to conventional in vitro fertilization in couples without male infertility concerns.Nature Medicine, Published online: 10 April 2025; doi:10.1038/s41591-025-03638-2
In a phase 1/2 trial in patients with advanced non-small-cell lung cancer (NSCLC), followed by a phase 2 trial in an EGFR-mutant selected population, treatment with the TROP2-targeting antibody–drug conjugate sacituzumab tirumotecan led to encouraging clinical response rates, especially in patients with EGFR-mutant NSCLC, which was supported by mechanistic data.